{"title":"双歧杆菌四活菌片治疗溃疡性结肠炎的疗效研究","authors":"Mengyuan Wang","doi":"10.26689/par.v7i5.5403","DOIUrl":null,"url":null,"abstract":"Objective: To study the therapeutic efficacy of patients with ulcerative colitis receiving Bifidobacterium quadruple viable tablets. Methods: 49 cases were selected from ulcerative colitis patients who attended the clinic from February 2021 to November 2022, and were randomly grouped into group A for addition of Bifidobacterium quadruple viable tablets treatment, and group B for conventional medication. The efficacy, inflammatory factors, nutritional indexes, and adverse reactions were compared between the groups. Results: The efficacy of UC patients in group A was higher than that in group B (P < 0.05); the inflammatory factors in group A were lower than that in group B (P < 0.05); nutritional indicators in group A were higher than that in group B (P < 0.05); and the adverse reactions of medication in UC patients in group A were lower than that in group B (P < 0.05). Conclusion: The treatment of UC patients with the addition of Bifidobacterium quadruple viable tablets can improve the nutritional status of the organism, inhibit the progression of inflammation, and is safe and efficient in treating ulcerative colitis.","PeriodicalId":20511,"journal":{"name":"Proceedings of Anticancer Research","volume":"2014 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Study on the Effect of Bifidobacterium Quadruple Viable Tablets in the Treatment of Ulcerative Colitis\",\"authors\":\"Mengyuan Wang\",\"doi\":\"10.26689/par.v7i5.5403\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: To study the therapeutic efficacy of patients with ulcerative colitis receiving Bifidobacterium quadruple viable tablets. Methods: 49 cases were selected from ulcerative colitis patients who attended the clinic from February 2021 to November 2022, and were randomly grouped into group A for addition of Bifidobacterium quadruple viable tablets treatment, and group B for conventional medication. The efficacy, inflammatory factors, nutritional indexes, and adverse reactions were compared between the groups. Results: The efficacy of UC patients in group A was higher than that in group B (P < 0.05); the inflammatory factors in group A were lower than that in group B (P < 0.05); nutritional indicators in group A were higher than that in group B (P < 0.05); and the adverse reactions of medication in UC patients in group A were lower than that in group B (P < 0.05). Conclusion: The treatment of UC patients with the addition of Bifidobacterium quadruple viable tablets can improve the nutritional status of the organism, inhibit the progression of inflammation, and is safe and efficient in treating ulcerative colitis.\",\"PeriodicalId\":20511,\"journal\":{\"name\":\"Proceedings of Anticancer Research\",\"volume\":\"2014 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Proceedings of Anticancer Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26689/par.v7i5.5403\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceedings of Anticancer Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26689/par.v7i5.5403","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Study on the Effect of Bifidobacterium Quadruple Viable Tablets in the Treatment of Ulcerative Colitis
Objective: To study the therapeutic efficacy of patients with ulcerative colitis receiving Bifidobacterium quadruple viable tablets. Methods: 49 cases were selected from ulcerative colitis patients who attended the clinic from February 2021 to November 2022, and were randomly grouped into group A for addition of Bifidobacterium quadruple viable tablets treatment, and group B for conventional medication. The efficacy, inflammatory factors, nutritional indexes, and adverse reactions were compared between the groups. Results: The efficacy of UC patients in group A was higher than that in group B (P < 0.05); the inflammatory factors in group A were lower than that in group B (P < 0.05); nutritional indicators in group A were higher than that in group B (P < 0.05); and the adverse reactions of medication in UC patients in group A were lower than that in group B (P < 0.05). Conclusion: The treatment of UC patients with the addition of Bifidobacterium quadruple viable tablets can improve the nutritional status of the organism, inhibit the progression of inflammation, and is safe and efficient in treating ulcerative colitis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
